Clinical Observation of Metoprolol Combined with Rosuvastatin in the Treatment of Elderly Coronary Heart Disease Complicated with Ventricular Arrhythmia
Objective To investigate the clinical efficacy of metoprolol combined with rosuvastatin in the treatment of elderly coronary heart disease(CHD)complicated with ventricular arrhythmia.Methods A total of 98 elderly patients with CHD and ventricular arrhythmia admitted to the hospital from January 2020 to February 2023 were selected and divided into the observation group and the control group by the random number table method,with 49 cases in each group.The patients in the two groups were given basic treatments(diuretics,vasodilators,anti-platelet aggregation drugs)and Rosuvastatin Calcium Tablets(orally),on this basis,the patients in the observation group were given Metoprolol Succinate Sustained-Release Tablets(orally).Both groups were treated continuously for three months.Results The total effective rate in the observation group was 95.92%,which was significantly higher than 81.63%in the control group(P<0.05).Compared with those before treatment,the frequencies of ventricular premature beat,paired ventricular premature beat and short-term paroxysmal ventricular tachycardia in the two groups significantly decreased after treatment,the left ventricular ejection fraction(LVEF)significantly increased,the left ventricular end-diastolic diameter(LVEDd)and left ventricular end-systolic diameter(LVESd)significantly shortened(P<0.05).Compared with those before treatment,the vascular endothelial growth factor(VEGF)and nitric oxide(NO)levels in the two groups significantly increased after treatment,the endothelin-1(ET-1),soluble growth stimulation expressed gene 2 protein(sST2),cardiac troponin I(cTnI)and N-terminal pro-brain natriuretic peptide(NT-proBNP)levels significantly decreased(P<0.05).Compared with those before treatment,the tumor necrosis factor-α(TNF-α),myeloperoxidase(MPO),hypersensitive C-reactive protein(hs-CRP),low density lipoprotein cholesterol(LDL-C),triglyceride(TG)and total cholesterol(TC)levels in the two groups significantly decreased after treatment,and the high density lipoprotein cholesterol(HDL-C)level significantly increased(P<0.05).Compared with that before treatment,the Visual Analogue Scale(VAS)score of the European Quality of Life Five Dimension 3 level(EQ-5D-3L)in the two groups significantly increased after treatment(P<0.05).The above indexes in the observation group showed greater improvement(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(12.24%vs.10.20%,P>0.05).Conclusion Metoprolol combined with rosuvastatin in the treatment of elderly CHD complicated with ventricular arrhythmia can decrease the frequency of ventricular arrhythmia,improve cardiac function,vascular endothelial function and blood lipid levels,inhibit myocardial injury and inflammatory reaction,and improve patients'quality of life.
国家科技期刊平台
NSTL
万方数据
